Fucosidosis is a rare autosomal recessive lysosomal disorder caused by ␣-fucosidase deficiency. We report a child with fucosidosis, second daughter of non-consanguineous parents, for whom biochemical diagnosis followed clinical evidence of the disease in her older sister. Based on previous experiences, the indication to transplant was considered. Since she lacked a matched sibling, an unrelated marrow donor was found. At prehematopoietic stem cell transplantation evaluation, first signs of neurological involvement were clinically detectable. MRI showed diffuse hypomyelination and auditory brainstem responses and somatic-sensorial evoked potentials were altered. Visual evoked potentials were normal, tortuosity in the retinal veins and peripapillary hemorrhages were detected. Bone marrow transplantation conditioning was with a regimen of busulphan, thiotepa and cyclophosphamide; in vivo Campath 1G, cyclosporin A and short course methotrexate were given to prevent graft-versus-host disease. 
a rare autosomal recessive lysosomal disorder caused by ␣-fucosidase deficiency producing accumulation and excretion of glycoproteins, glycolipids and oligosaccharides containing fucose moieties. 1, 2 Over the last few years, several storage diseases have been treated with hematopoietic stem cell transplantation (HSCT). [3] [4] [5] [6] The enzymatic activity of white blood cells has been proven to rise to normal levels after HSCT. 7 Moreover, the differentiation of donor monocytes into tissue-specific cells such as Kupfer cells, Ito cells, pulmonary or peritoneal macrophages, lymphoid or histiocytic cells of the spleen and lymph nodes or dendritic cells of the skin causes the clearance of the accumulated substrate in many organs. 8 The correction of enzymatic levels has also been demonstrated in the CNS where new microglia and astroglia were shown to originate in the donor's macrophagic system. [9] [10] [11] [12] [13] Persistence of engraftment makes it possible to maintain the turnover of these cells and accounts for clinical improvement after HSCT. Intracellular enzyme transfer and uptake of donor-derived enzyme in plasma contribute to improving the advantageous effects of HSCT in these diseases. In the canine model, early HSCT proved to be useful in preventing clinical onset of fucosidosis and in maintaining normal enzymatic levels. 14 Clinical improvement has been reported in human fucosidosis after HSCT. 15, 16 In this paper we report on the long-term outcome of fucosidosis in a patient treated with unrelated donor (UD) HSCT.
Case report
We report on the outcome of the second daughter of nonconsanguineous parents, for whom diagnosis followed clinical evidence of the disease in her sister.
At the age of 18 months, the patient's older sister underwent cranial MRI which showed a diffuse hypomyelination involving the lenticular nuclei myelination. Her height was Ͼ75th centile, weight and head circumference were Ͼ95th centile. Clinical examination showed dorsal kyphosis, lumbar lordosis, moderate facial dysmorphia, strabism, gingival hypertrophy, angiokeratoma, uncertain gait and absence of speech. The level of ␣-fucosidase in lymphocytes was 0.7 nmol/mg/h (NR 52 ± 11.7). Parents' levels (23.5 and 21 nmol/mg/h) were compatible with a casual carrier.
Bone Marrow Transplantation
In AC, the subject of our report, ␣-fucosidase levels were below the normal range, namely 1.4 nmol/mg/h (NR 52 ± 11.7) in lymphocytes and 7.2 nmol/mg/h (NR 595 ± 193) in plasma; ␣-fucosidase was undetectable in the cerebrospinal fluid.
At diagnosis AC was 5 months old and asymptomatic. Factors such as young age, absence of neurological symptoms as well as favorable data obtained in the animal model suggested she was a suitable candidate for HSCT. As there were no other siblings and the mother, mismatched at one HLA-B locus, was excluded because of her low enzyme levels, the search for an unrelated donor was activated in July 1995.
Donor search was facilitated by the Italian Bone Marrow Donor Registry (IBMDR) and was run in worldwide registries. A 34-year-old woman, HLA-A,B,DRB1 matched and DRB4, DPB1 mismatched, was identified in October 1995 in the A. Nolan Registry. The donor and the recipient had the same blood group and were negative for exposure to CMV.
Results

Pre-HSCT assessment
Clinical evaluation performed before HSCT at the age of 10 months, showed moderate liver enlargement and absence of splenomegaly. Height and weight were between the 75th and 90th centile. First signs of psychomotor delay were clinically detectable, consisting of mild hypotonia, weakness and neonatal reactions. Cognitive functions were studied with the Brunet-Lezine test which showed speech and posture of an 8-month-old infant and coordination of a 9-month-old infant. The patient showed interest in her surroundings and interacted by means of facial expression and modulated phonemes. Psychomotor development quotient (PDQ) was 90, auditory brainstem responses (ABRs) and somato-sensorial evoked potentials (SSEPs) were altered, visual evoked potentials (VEPs) were normal and the ophthalmologic evaluation showed peripapillar retinal hemorrhages and tortuosity of retinal veins. Cranial MRI images were similar to those of the older sister showing a diffuse hypomyelination 17, 18 of the white matter and of ventricular nuclei of both cerebral hemispheres and cerebellar white matter (Figures 1 and 2 ).
HSCT
The 11-month-old patient was conditioned for HSCT with busulphan 22 mg/kg given in four doses per day from days −10 to −6 (dose adjusted according to plasma levels to obtain a steady-state concentration), thiothepa 6 mg/kg divided in two doses on day −5, and cyclophosphamide 200 mg/kg in four doses from day −4 to 1. GVHD prophylaxis consisted of in vivo Campath 1G (0.2 mg/kg/day) from day −4 to −1, cyclosporin A 5 mg/kg on days −1 and 0 and 3 mg/kg from day +1, methotrexate 10 mg/m 2 on days +1, +3, +6, +11. She received an infusion of unmanipulated bone marrow containing 18 × 10 8 nucleated cells/kg recipient body weight. Hematopoietic reconstitution was rapid, with both neutrophil and platelet counts reaching levels higher than 0.5 × 10 9 /l and 50 × 10 9 /l, respectively, by day 16. Full donor engraftment was demonstrated on day +90 by short tandem repeat (STR) polymorphisms. 19 The patient developed steroid-responsive grade II cutaneous aGVHD on day +64, and had a transient episode of idiopathic thrombocytopenic purpura (ITP) at 6 months from HSCT. Recurrent episodes of acute febrile neutrophilic dermatosis with pulmonary infiltrates and pleural effusion consistent with Sweet's syndrome and repeated septic complications related to central venous catheter also occurred. Cortisone therapy was discontinued 24 months after HSCT and cyclosporin after 33 months.
Follow-up
Enzymatic follow-up (Table 1) showed a progressive rise of ␣-fucosidase levels in lymphocytes, plasma and CSF.
MRI examination at 4 months after HSCT showed similar images of white matter and a moderate enlargement of ventricular system and subarachnoid spaces probably due to atrophy. A slight improvement of white matter myelination was observed 13 months after HSCT and become more evident at 24 months compared to the older sister's images at the same age. The 32-month images showed a good myelination with small residual areas of hypomyelination and slight cerebellar atrophy. This improvement (Figure 3) . After an initial growth decrease, height and weight assessment showed an impressive increase simultaneously with high levels of GH and IGF-1 and pituitary hypertrophy at MRI images, probably due to compensation after steroid treatment. Endocrinological follow-up excluded hypothalamic-pituitary axis involvement. Initially, clinical followup showed a progressive decay. In fact the patient showed a worsening of hypotonia, onset of a tremor, poor coordination and loss of sphincteric control.
Psychomotor decay occurred with fall of PDQ to 35 after 19 months. However, after the first year from HSCT progressive improvement was observed. At 42 months of age, Brunet-Lezine evaluation showed posture and coordination of 27 months of age and sociality of 24 months. Speech development at 18 months of age was delayed ( Table 2) . PDQ is now 48. The patient walked alone at the age of 30 months with an uncertain gait ascribable to hypotonia associated with ligament laxity. Moreover, lower limb vagus deformity still persists. Deglutition problems, involving upper respiratory tract system infections, have been corrected. A = locomotor skills; B = coordination; C = speech; D = social skills; Q = developmental quotient.
Discussion
The reported case fits the picture of fucosidosis. The natural history of the disease is characterized by gradual loss of intellectual capacity resulting in dementia followed by death due to central nervous system deterioration. In our patient, 4 years after HSCT performed at 1 year of age, MRI findings had improved considerably and the clinical course was completely different from that of her older sibling who died at the age of 7 years after a long period of paraplegia and vegetative status. To our knowledge, this is the first paper reporting on so long-term an outcome of transplantation in a patient with fucosidosis. It confirms that stable engraftment of allogeneic hematopoietic cells with normal enzymatic activity may correct fucosidosis in a human.
The use of HSCT in storage diseases must be accurately evaluated before considering this procedure for a child with fucosidosis. Diagnosis must be made at an early disease stage because CNS deterioration progresses unavoidably to death and, as shown in animal models, may not be corrected in cases where it is already present at the time of HSCT.
The encouraging results of HSCT in patients suffering from storage diseases suggest that this is a valid tool in the treatment of this otherwise lethal disease. However, most of these patients lack a healthy HLA-histocompatible sibling donor and, moreover, even in the presence of a partially matched parent, their low enzymatic activity raises questions on their use as a donor. Recently, the increased availability of volunteer marrow donors among international registries offers a concrete alternative for allowing transplantation of most of these patients within a reasonable time from diagnosis. In fact, the time between diagnosis and transplant is a decisive factor in predicting a favorable outcome for these patients. We were able to perform the transplant 6 months after diagnosis which we considered an acceptable time-frame. In this regard the use of cord blood could provide a further opportunity to accelerate the procedure. Nonetheless, throughout this period a progressive neuromotor deterioration was observed.
This loss of performance could be explained by disease progression before the migration of enzyme producing cells deriving from donor's hematopoietic precursors into CNS. Moreover, drug-related involvement of CNS could contribute to neurological deterioration. In fact, cranial MRI images showing atrophy and ventricular dilatation are commonly observed in young children during the first months after HSCT for hematological diseases. Unfortunately, we lack data on ␣-fucosidase production in CSF within the first 2 years after HSCT. However, data from canine models 14 showing a substantial increase of CNS enzyme activity only 6 months after successful engraftment seem to support this hypothesis.
Although patients with storage diseases are at high risk of rejection because of their young age and of their immune system not impaired by prior chemotherapy, busulfan was preferred to TBI as conditioning regimen to avoid further toxicity in organs already damaged by the underlying disease. Prior experiences of conditioning regimen, including thiotepa and cyclophosphamide, showed an encouraging percentage of engraftment in patients who underwent HSCT for inborn errors like thalassemia, Wiskott-Aldrich syndrome, osteopetrosis, Hunter syndrome and Schwachman syndrome. 20 The improvement of clinical symptoms in our patient could be explained by a rise in enzyme levels although a milder form of the disease could also be due to an intrafamilial variation. 21 Nevertheless, the associated improvement of MRI images strongly support the hypothesis that the progressive neuromotor improvement could be related to the rise of enzyme activity following HSCT. A longer followup is required to better evaluate the HSCT benefit in terms of neuromotor development and quality of life of the child. However, while waiting for gene therapy to become a real alternative, early HSCT, in pre-symptomatic patients, seems to represent a valid option to cure this otherwise lethal disease. 22 
